
Axsome Therapeutics (AXSM) Stock Forecast & Price Target
Axsome Therapeutics (AXSM) Analyst Ratings
Bulls say
Axsome Therapeutics is well-positioned for success with their diverse pipeline, including Solriamfetol for multiple indications and other candidates in clinical development. The company has a recent successful drug launch and has seen strong revenue growth. Positive results in Phase 3 trials for ADHD in adults and plans for treating excessive daytime sleepiness show promising potential for future growth and success.
Bears say
Axsome Therapeutics is currently facing significant risks in achieving their projected valuation. The company has a high discount rate of 12% applied to future cash flows, and potential setbacks in clinical trials could hinder the success of their pipeline products. While their current drug, SUNOSI, has demonstrated growth in sales, its market share is expected to decline over time due to increased competition. Additionally, the company faces risks related to R&D, regulatory hurdles, and competition in the CNS market.
This aggregate rating is based on analysts' research of Axsome Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Axsome Therapeutics (AXSM) Analyst Forecast & Price Prediction
Start investing in Axsome Therapeutics (AXSM)
Order type
Buy in
Order amount
Est. shares
0 shares